COVID-19 and type 1 diabetes: dealing with the difficult duo
- PDF / 250,734 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 78 Downloads / 124 Views
REVIEW ARTICLE
COVID-19 and type 1 diabetes: dealing with the difficult duo Subhankar Chowdhury 1 & Soumik Goswami 2 Received: 6 June 2020 / Accepted: 16 June 2020 # Research Society for Study of Diabetes in India 2020
Abstract Background Coronavirus disease 2019 (COVID-19) has aroused global health concerns, particularly in relation to diabetes where it has been associated with poorer outcomes. The bulk of the evolving evidence in diabetes and COVID-19 relates to type 2 diabetes (T2D). Since there are a significant number of patients with type 1 diabetes (T1D) with unique concerns and challenges during the ongoing COVID-19 pandemic, we reviewed existing literature, relevant websites, and related guidelines to form this narrative review to help address key questions in this area. Methods We systematically searched the PubMed database up to May 31, 2020, and retrieved all the articles published on T1D and COVID-19. Results We found 18 relevant articles, each of which carried a part of the evidence regarding the risk of contracting COVID-19 in patients with T1D, effect of COVID-19 on development of T1D, outcomes in T1D with COVID-19, and special management issues in T1D in the light of COVID-19. These have been documented in the present review. Conclusion COVID-19 with T1D presents special challenges. While the available evidence does shed some light, we need more evidence to deal with this difficult duo. Keywords COVID-19 . SARS-CoV-2 . Type 1 diabetes . Diabetic ketoacidosis
Coronavirus disease 2019 (COVID-19) epidemic caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) emerged in Wuhan, China, in December 2019 and has progressed rapidly into a pandemic since the first quarter of 2020 [1]. COVID-19 is commonly characterised by fever, cough, fatigue, shortness of breath, pneumonia, and other respiratory tract symptoms and may even progress to death in some [2]. Patients with older age, hypertension, male gender, heart disease, cerebrovascular disease, kidney disease, hyperglycemia, or history of smoking have been shown to have a higher risk of developing more severe disease and subsequent mortality [3–6]. There have been several publications from the global scientific community on COVID-!9 in type 2 diabetes (T2D) but markedly fewer looking at type 1 diabetes (T1D). T1D constitutes about 5% of all diagnosed cases of diabetes and its global incidence is increasing at * Soumik Goswami [email protected] 1
Department of Endocrinology and Metabolism, IPGME&R and SSKM Hospital, Kolkata, India
2
Department of Endocrinology, Nilratan Sircar Medical College, 138 AJC Bose Road, Kolkata 700014, India
about 3% every year [7]. Given the global burden of T1D and unique challenges in treating T1D (more so in developing nations like India), this narrative review attempts to address key questions regarding COVID-19 and T1D. We systematically searched the PubMed database up to May 31, 2020, and retrieved 18 articles published on T1D and COVID-19 besides looking at relevant websites and related guidel
Data Loading...
